Charles Schwab’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-531,475
| Closed | -$8.36M | – | 3711 |
|
|
2024
Q1 | $8.36M | Buy |
531,475
+16,174
| +3% | +$249K | ﹤0.01% | 2073 |
|
|
2023
Q4 | $8.31M | Buy |
515,301
+13,716
| +3% | +$175K | ﹤0.01% | 2084 |
|
|
2023
Q3 | $6.38M | Buy |
501,585
+8,325
| +2% | +$115K | ﹤0.01% | 2139 |
|
|
2023
Q2 | $6.95M | Buy |
493,260
+36,615
| +8% | +$524K | ﹤0.01% | 2078 |
|
|
2023
Q1 | $7.06M | Buy |
456,645
+96,827
| +27% | +$1.62M | ﹤0.01% | 2047 |
|
|
2022
Q4 | $5.9M | Buy |
359,818
+12,520
| +4% | +$204K | ﹤0.01% | 2133 |
|
|
2022
Q3 | $6.43M | Buy |
347,298
+19,140
| +6% | +$300K | ﹤0.01% | 2089 |
|
|
2022
Q2 | $4.32M | Buy |
328,158
+52,829
| +19% | +$583K | ﹤0.01% | 2247 |
|
|
2022
Q1 | $2.55M | Sell |
275,329
-18,971
| -6% | -$161K | ﹤0.01% | 2560 |
|
|
2021
Q4 | $2.88M | Buy |
294,300
+8,670
| +3% | +$163K | ﹤0.01% | 2579 |
|
|
2021
Q3 | $9.71M | Buy |
285,630
+8,877
| +3% | +$283K | ﹤0.01% | 2026 |
|
|
2021
Q2 | $10.1M | Buy |
276,753
+6,369
| +2% | +$247K | ﹤0.01% | 1994 |
|
|
2021
Q1 | $12.1M | Buy |
270,384
+11,151
| +4% | +$519K | ﹤0.01% | 1844 |
|
|
2020
Q4 | $14.8M | Buy |
259,233
+6,421
| +3% | +$381K | 0.01% | 1613 |
|
|
2020
Q3 | $13M | Buy |
252,812
+81,803
| +48% | +$4.01M | 0.01% | 1504 |
|
|
2020
Q2 | $10.2M | Buy |
171,009
+46,488
| +37% | +$2.49M | 0.01% | 1639 |
|
|
2020
Q1 | $5.13M | Buy |
124,521
+8,377
| +7% | +$465K | ﹤0.01% | 1822 |
|
|
2019
Q4 | $7.23M | Buy |
116,144
+7,530
| +7% | +$358K | ﹤0.01% | 1835 |
|
|
2019
Q3 | $3.69M | Buy |
108,614
+22,266
| +26% | +$659K | ﹤0.01% | 2134 |
|
|
2019
Q2 | $1.95M | Buy |
86,348
+13,528
| +19% | +$317K | ﹤0.01% | 2379 |
|
|
2019
Q1 | $1.69M | Buy |
72,820
+3,184
| +5% | +$83.3K | ﹤0.01% | 2408 |
|
|
2018
Q4 | $1.46M | Sell |
69,636
-1,120
| -2% | -$27.5K | ﹤0.01% | 2425 |
|
|
2018
Q3 | $2.74M | Buy |
70,756
+10,188
| +17% | +$376K | ﹤0.01% | 2329 |
|
|
2018
Q2 | $2.38M | Buy |
60,568
+26,777
| +79% | +$788K | ﹤0.01% | 2320 |
|
|
2018
Q1 | $678K | Buy |
33,791
+5,737
| +20% | +$145K | ﹤0.01% | 2646 |
|
|
2017
Q4 | $636K | Buy |
+28,054
| New | +$549K | ﹤0.01% | 2664 |
|
Other funds holding DCPH
Charles Schwab's DCPH Position: Q2 2024 in Review
Charles Schwab sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 531,475 shares — an estimated $8.36M sold.
Charles Schwab first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $14.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Charles Schwab reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Charles Schwab sold 531,475 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $8.36M.
- Charles Schwab first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- Charles Schwab's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $14.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.